Skip to main content
Back
RPRX logo

Royalty Pharma plc

Data quality: 100%
RPRX
NASDAQ Healthcare Biotechnology
$45.61
▲ $0.25 (0.55%)
Mkt Cap: 19.54B
Day Range
$45.05 $46.06
52-Week Range
$29.66 $47.86
Volume
3,312,388
50D / 200D Avg
$43.70 / $38.65
Prev Close
$45.36

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 25.4 0.4
P/B 3.0 2.9
ROE % 11.5 3.8
Net Margin % 32.4 3.9
Rev Growth 5Y % 1.0 10.0
D/E 1.4 0.2

Key Takeaways

Revenue grew 0.96% annually over 5 years — modest growth
Earnings declined -10.25% over the past year
ROE of 11.49% — decent returns on equity
Net margin of 32.42% shows strong profitability
Generating 2.49B in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 4.10%

Growth

Revenue Growth (5Y)
0.96%
Revenue (1Y)5.06%
Earnings (1Y)-10.25%
FCF Growth (3Y)-8.71%

Quality

Return on Equity
11.49%
ROIC7.58%
Net Margin32.42%
Op. Margin65.58%

Safety

Debt / Equity
1.38
Current Ratio0.97
Interest Coverage5.07

Valuation

P/E Ratio
25.35
P/B Ratio3.02
EV/EBITDA17.87
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 5.06% Revenue Growth (3Y) 0.50%
Earnings Growth (1Y) -10.25% Earnings Growth (3Y) -17.58%
Revenue Growth (5Y) 0.96% Earnings Growth (5Y) 5.61%
Profitability
Revenue (TTM) 2.38B Net Income (TTM) 770.95M
ROE 11.49% ROA 3.93%
Gross Margin 100.00% Operating Margin 65.58%
Net Margin 32.42% Free Cash Flow (TTM) 2.49B
ROIC 7.58% FCF Growth (3Y) -8.71%
Safety
Debt / Equity 1.38 Current Ratio 0.97
Interest Coverage 5.07 Dividend Yield 0.02%
Valuation
P/E Ratio 25.35 P/B Ratio 3.02
P/S Ratio 8.22 PEG Ratio 1.04
EV/EBITDA 17.87 Dividend Yield 0.02%
Market Cap 19.54B Enterprise Value 27.87B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.38B 2.26B 2.35B 2.24B 2.29B
Net Income 770.95M 858.98M 1.13B 42.83M 619.73M
EPS (Diluted) 1.80 1.45 2.53 0.10 1.49
Gross Profit 2.38B 2.26B 2.35B 2.24B 2.29B
Operating Income 1.56B 1.29B 1.49B 307.07M 1.43B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 19.62B 18.22B 16.38B 16.81B 17.52B
Total Liabilities 9.91B 7.88B 6.30B 7.29B 7.27B
Shareholders' Equity 6.48B 6.95B 6.53B 5.63B 5.78B
Total Debt 8.95B 7.61B 6.14B 7.12B 7.10B
Cash & Equivalents 618.70M 929.03M 477.01M 1.71B 1.54B
Current Assets 619.00M 1.80B 1.27B 2.55B 2.88B
Current Liabilities 636.21M 1.25B 161.38M 1.17B 171.25M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#346 of 1024
53

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026